Tg Therapeutics's 15-minute chart shows RSI Oversold and KDJ Golden Cross.

Tg Therapeutics' 15-minute chart has triggered an oversold reading on the Relative Strength Index (RSI) and a Golden Cross on the Kinetick Directional Index (KDJ) at 08/26/2025 10:00. This suggests that the stock price has declined rapidly and fallen below its fundamental support level, and momentum is shifting towards an upward trend with potential for further price appreciation.

Tg Therapeutics' (NASDAQ: TGTX) stock has shown signs of a potential upward trend, as indicated by the 15-minute chart triggering an oversold reading on the Relative Strength Index (RSI) and a Golden Cross on the Kinetick Directional Index (KDJ) at 08/26/2025 10:00. These technical indicators suggest that the stock price has declined rapidly and fallen below its fundamental support level, with momentum shifting towards an upward trend. This could indicate further price appreciation.

The 15-minute chart's RSI reading below 30 indicates that the stock is oversold, which typically signals a potential buying opportunity. The Golden Cross on the KDJ, where the 9-period and 26-period moving averages cross above each other, further suggests a bullish trend. This combination of technical indicators points to a possible reversal in the stock's downward trajectory.

Tg Therapeutics' recent financial performance has been mixed. The company reported a quarterly revenue of $141.1 million in Q2'25, which was below analyst estimates of $147.76 million, and missed earnings expectations with an EPS of $0.17 [2]. Despite this, the company has shown resilience in its cash position and has guided for full year operating expenses of $300M. The company expects its cash and Briumvi revenues to be sufficient to fund the business.

The company's Briumvi drug, a treatment for multiple sclerosis, is still on track to reach blockbuster status, with analyst estimates for revenues reaching $1B by 2027. The drug has shown strong growth in the US market, with revenues of $138.8 million in Q2'25. However, the company has faced some challenges with slower sales growth in recent quarters.

The company's development pipeline includes a phase 3 trial for subcutaneous Briumvi, which could provide a significant revenue boost if successful. The company has also launched a television advertising campaign for Briumvi, which it suggests is already having an impact on patient awareness.

Investors should closely monitor Tg Therapeutics' earnings reports and clinical trial data for further insights into the company's growth prospects. The recent technical indicators suggest that the stock could be undervalued, but investors should be cautious and conduct thorough due diligence.

References:
[1] https://seekingalpha.com/article/4814885-tg-therapeutics-looking-for-stimulus-for-turnaround
[2] https://www.marketbeat.com/instant-alerts/filing-tg-therapeutics-inc-tgtx-position-decreased-by-1832-asset-management-lp-2025-08-23/